Thomas Forst

Summary

Affiliation: Institute for Clinical Research and Development
Country: Germany

Publications

  1. ncbi Pilot study for the evaluation of morphological and functional changes in retinal blood flow in patients with insulin resistance and/or type 2 diabetes mellitus
    Thomas Forst
    Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 6:163-8. 2012
  2. ncbi Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the
    Markolf Hanefeld
    GWT TUD mbH, Fiedlerstr 34, 01307 Dresden, Germany
    Cardiovasc Diabetol 10:65. 2011
  3. ncbi Effects of C-peptide on microvascular blood flow and blood hemorheology
    T Forst
    Institute for Clinical Research and Development, Mainz, Germany
    Exp Diabesity Res 5:51-64. 2004
  4. ncbi IRIS II study: the IRIS II score--assessment of a new clinical algorithm for the classification of insulin resistance in patients with Type 2 diabetes
    T Forst
    Institute for Clinical Research and Development, Mainz, Germany
    Diabet Med 21:1149-53. 2004
  5. ncbi Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients
    T Forst
    Institute for Clinical Research and Development, Mainz, Germany
    Horm Metab Res 41:123-31. 2009
  6. ncbi Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes
    T Forst
    Institute for Clinical Research and Development, Clinical Department, Mainz, Germany
    Diabetes Obes Metab 12:437-41. 2010
  7. ncbi Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetes
    Thomas Forst
    Institute for Clinical Research and Development, Parcusstrasse 8, Mainz D 55116, Germany
    J Diabetes Complications 19:128-32. 2005
  8. ncbi [Current laboratory parameters in the differential diagnosis of type 2 diabetes mellitus. Proinsulin, adiponectin and others]
    T Forst
    Institut für klinische Forschung und Entwicklung, Mainz, Mainz, Germany
    Dtsch Med Wochenschr 131:S268-73. 2006
  9. ncbi Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes
    T Forst
    Institute for Clinical Research and Development, Mainz, Germany
    Horm Metab Res 37:521-7. 2005
  10. ncbi Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2
    Thomas Forst
    Institute for Clinical Research and Development, Mainz, Germany
    Microcirculation 12:543-50. 2005

Collaborators

Detail Information

Publications85

  1. ncbi Pilot study for the evaluation of morphological and functional changes in retinal blood flow in patients with insulin resistance and/or type 2 diabetes mellitus
    Thomas Forst
    Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 6:163-8. 2012
    ..The aim of this study was to investigate early morphological and functional pathology in the retinal micro-circulation in patients with insulin resistance and/or type 2 diabetes mellitus (T2DM)...
  2. ncbi Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the
    Markolf Hanefeld
    GWT TUD mbH, Fiedlerstr 34, 01307 Dresden, Germany
    Cardiovasc Diabetol 10:65. 2011
    ..We analyzed specific effects of an add-on therapy with pioglitazone compared to metformin and their combination in patients with basal insulin treatment on biomarkers of CV risk...
  3. ncbi Effects of C-peptide on microvascular blood flow and blood hemorheology
    T Forst
    Institute for Clinical Research and Development, Mainz, Germany
    Exp Diabesity Res 5:51-64. 2004
    ..In conclusion, C-peptide improves microvascular function and blood flow in type 1 diabetic patients by interfering with vascular and rheological components of microvascular blood flow...
  4. ncbi IRIS II study: the IRIS II score--assessment of a new clinical algorithm for the classification of insulin resistance in patients with Type 2 diabetes
    T Forst
    Institute for Clinical Research and Development, Mainz, Germany
    Diabet Med 21:1149-53. 2004
    ..The aim of our study was to compute a new algorithm for estimating insulin resistance in a routine clinical setting...
  5. ncbi Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients
    T Forst
    Institute for Clinical Research and Development, Mainz, Germany
    Horm Metab Res 41:123-31. 2009
    ..The coexistence of insulin resistance with functional beta cell failure results in loss of blood glucose control especially after a meal and increases the cardiovascular risk of these patients far beyond the increased glucose levels...
  6. ncbi Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes
    T Forst
    Institute for Clinical Research and Development, Clinical Department, Mainz, Germany
    Diabetes Obes Metab 12:437-41. 2010
    ..This open-label, parallel-group, two-arm, pilot study compared the beta-cell protective effect of adding insulin glargine (GLA) vs. NPH insulin to ongoing metformin...
  7. ncbi Impact of insulin on microvascular blood flow and endothelial cell function in the postprandial state in patients with Type 1 diabetes
    Thomas Forst
    Institute for Clinical Research and Development, Parcusstrasse 8, Mainz D 55116, Germany
    J Diabetes Complications 19:128-32. 2005
    ..0 (19.0-49.3) vs. 20.9 (9.7-26.1) AU, P=.0001]. Postprandial microvascular blood flow is disturbed in patients with Type 1 diabetes. Improvement of postprandial metabolic control was found to improve postprandial microvascular function...
  8. ncbi [Current laboratory parameters in the differential diagnosis of type 2 diabetes mellitus. Proinsulin, adiponectin and others]
    T Forst
    Institut für klinische Forschung und Entwicklung, Mainz, Mainz, Germany
    Dtsch Med Wochenschr 131:S268-73. 2006
    ..Measurement of inflammation, by high sensitive CRP might add further information about the cardiovascular risk of a patient with type 2 diabetes...
  9. ncbi Pharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetes
    T Forst
    Institute for Clinical Research and Development, Mainz, Germany
    Horm Metab Res 37:521-7. 2005
    ..37; p < 0.0001). Measurement of adiponectin and intact proinsulin enables characterization of the metabolic situation and an estimation of atherosclerotic risk in patients with type 2 diabetes...
  10. ncbi Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2
    Thomas Forst
    Institute for Clinical Research and Development, Mainz, Germany
    Microcirculation 12:543-50. 2005
    ..The study was performed to investigate the effect of improving metabolic control with pioglitazone in comparison to glimepiride on microvascular function in patients with diabetes mellitus type 2...
  11. ncbi Changes in insulin resistance and cardiovascular risk induced by PPARgamma activation have no impact on RBP4 plasma concentrations in nondiabetic patients
    A Pfutzner
    Institute for Clinical Research and Development, Mainz, Germany
    Horm Metab Res 41:202-6. 2009
    ..The regulation of RBP4 expression and secretion occurs through biochemical pathways independent from those influenced by pioglitazone or simvastatin...
  12. ncbi Impact of environmental temperature on skin thickness and microvascular blood flow in subjects with and without diabetes
    T Forst
    Institute for Clinical Research and Development and Department of Endocrinology and Diabetes, Johannes Gutenberg University, Mainz, Germany
    Diabetes Technol Ther 8:94-101. 2006
    ..Our study was performed to investigate the effect of changes in ambient temperature on skin thickness and microvascular skin blood flow in subjects with and without diabetes at the lower forearm...
  13. ncbi Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device
    Thomas Forst
    Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 11:87-92. 2009
    ....
  14. ncbi Impact of low frequency transcutaneous electrical nerve stimulation on symptomatic diabetic neuropathy using the new Salutaris device
    T Forst
    Institute for Clinical Research and Development ikfe GmbH, Mainz, Germany
    Diabetes Nutr Metab 17:163-8. 2004
    ..In conclusion, our study indicates that the new TENS device "Salutaris" is a convenient, non-pharmacological option for primary or adjuvant treatment of painful diabetic neuropathy...
  15. ncbi Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus
    Thomas Forst
    Institute for Clinical Research and Development, University of Mainz, Germany
    Clin Sci (Lond) 119:345-51. 2010
    ..47; P<0.05). This is the first study showing an improvement in EI during treatment with PIO, which was associated with an increase in adiponectin and a decrease in intact proinsulin levels, but independent of glycaemic control...
  16. ncbi Linagliptin, a dipeptidyl peptidase-4 inhibitor with a unique pharmacological profile, and efficacy in a broad range of patients with type 2 diabetes
    Thomas Forst
    Institute for Clinical Research and Development, Mainz, Germany
    Expert Opin Pharmacother 13:101-10. 2012
    ..It has a unique pharmacological profile within its class and, unlike other DPP-4 inhibitors, linagliptin does not require dose adjustment in patients with renal impairment...
  17. ncbi Role of C-Peptide in the regulation of microvascular blood flow
    T Forst
    Medical Department, Institute for Clinical Research and Development, 55116 Mainz, Germany
    Exp Diabetes Res 2008:176245. 2008
    ....
  18. ncbi Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in early type 2 diabetes
    T Forst
    Institute for Clinical Research and Development, Mainz, Germany
    Exp Clin Endocrinol Diabetes 111:97-103. 2003
    ..In addition, use of LP was associated with a decrease in fasting C-peptide and proinsulin levels, suggesting a potential down regulation of endogenous insulin production and improved proinsulin processing efficiency...
  19. ncbi Review of approved pioglitazone combinations for type 2 diabetes
    Thomas Forst
    IKFE Institute for Clinical Research and Development, Parcusstr 8, D 5116 Mainz, Germany
    Expert Opin Pharmacother 12:1571-84. 2011
    ..The treating of T2DM patients by addressing not only glucose control, but also the underlying pathophysiological etiology might help to improve patient prognosis in the long run, especially with regard to the vascular complications...
  20. ncbi Postprandial vascular effects of VIAject compared with insulin lispro and regular human insulin in patients with type 2 diabetes
    Thomas Forst
    Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Care 33:116-20. 2010
    ..This study compared the effect of VIAject with human regular insulin and insulin lispro on postprandial oxidative stress and endothelial function in patients with type 2 diabetes...
  21. ncbi Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease
    T Forst
    Institute for Clinical Research and Development, Parcusstrasse 8, D 55116 Mainz, Germany
    Atherosclerosis 197:311-7. 2008
    ..No changes in these parameters could be observed during placebo treatment. Even before effects on glucose metabolism could be obtained, pioglitazone exerts immediate effects on plasma markers of plaque vulnerability and inflammation...
  22. ncbi [The diagnosis of an autonomic dysfunction of the lower limb as a major aspect of the neurological investigation and risk assessment of a diabetic foot syndrome]
    Th Forst
    Institut für klinische Forschung und Entwicklung, Mainz
    MMW Fortschr Med 146:35-8. 2004
    ..A purposeful assessment of risk and prevention of neurotrophic damage in the lower limb is possible only on the basis of a rigorous differential diagnostic work-up of the diabetic polyneuropathy...
  23. ncbi Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk
    Thomas Forst
    Medical Director, Institute for Clinical Research and Development, Mainz, Germany
    Diab Vasc Dis Res 5:298-303. 2008
    ..05 respectively). Atorvastatin significantly improved IMT and vascular elasticity. Co-administration of pioglitazone provided additional effects on endothelial function, lipid profile and laboratory markers of inflammation...
  24. ncbi Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain
    Thomas Forst
    Institute for Clinical Research and Development and Department of Endocrinology, University of Mainz, Mainz, Germany
    Br J Clin Pharmacol 64:75-82. 2007
    ..The purpose of the current study was to establish the safety and maximal tolerated dose of CNS 5161 HCl...
  25. ncbi Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk--the PIOSTAT Study
    Thomas Forst
    Institute for Clinical Research and Development, Medical Department, D 55116 Mainz, Germany
    Metabolism 56:491-6. 2007
    ..05) during PIO/SIM treatment. Lipid parameters improved during SIM treatment but not during PIO treatment. Combined treatment with PIO/SIM was superior in improving overall cardiovascular risk profile than every single drug...
  26. ncbi Combined pioglitazone and metformin treatment maintains the beneficial effect of short-term insulin infusion in patients with type 2 diabetes: results from a pilot study
    Petra B Musholt
    Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 3:1442-50. 2009
    ..The aim of our study was to examine the efficacy of short-term intravenous insulin intervention followed by oral pioglitazone/metformin therapy to prevent patients from continuous insulin application...
  27. ncbi Effect of insulin glulisine on microvascular blood flow and endothelial function in the postprandial state
    Clothilde Hohberg
    Institute for Clinical Research and Development, Parcusstrasse 8, D 55116 Mainz, Germany
    Diabetes Care 31:1021-5. 2008
    ..To investigate the effect of insulin glulisine on postprandial microvascular blood flow in type 2 diabetes...
  28. ncbi The fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix study
    Thomas Schondorf
    Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 5:426-32. 2011
    ..This study investigates the impact of a pioglitazone plus metformin therapy on biomarkers of inflammation and platelet activation in comparison to a treatment with glimepiride plus metformin...
  29. ncbi Relaxin expression correlates significantly with serum fibrinogen variation in response to antidiabetic treatment in women with type 2 diabetes mellitus
    Thomas Schondorf
    Institute for Clinical Research and Development, Mainz, Germany
    Gynecol Endocrinol 23:356-60. 2007
    ..Therefore, the present study investigated the correlation of relaxin expression with fibrinogen levels in diabetes patients undergoing oral antidiabetic treatment...
  30. ncbi Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    Metabolism 55:20-5. 2006
    ..In conclusion, our short-term investigation of rosiglitazone action provides further experimental support for the rationale of combining rosiglitazone with sulfonylurea drugs in patients with type 2 diabetes...
  31. ncbi PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia
    Andreas Pfutzner
    Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 13:637-43. 2011
    ..The aim of our study was to investigate the effect of a fixed pioglitazone?+?metformin (PM) combination (vs. glimepiride?+?metformin [GM]) on diabetic dyslipidemia...
  32. ncbi Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study
    Andreas Pfutzner
    Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 12:599-604. 2010
    ....
  33. ncbi Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat study
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    Clin Lab 55:275-81. 2009
    ..We evaluated the plausibility of results derived from a new ELISA (Immundiagnostik, Bensheim, Germany) in comparison to a different ELISA test (Mercodia, Uppsala, Sweden)...
  34. ncbi IRIS II Study: Sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistance
    Matthias R Langenfeld
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 6:836-43. 2004
    ....
  35. ncbi Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Parcusstrasse 8, D 55116 Mainz, Germany
    J Am Coll Cardiol 45:1925-31. 2005
    ..This study was performed to assess whether the anti-inflammatory and antiatherogenic effects of pioglitazone suggested by animal experiments are reproducible in man and independent from improvements in metabolic control...
  36. ncbi Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 5:989-98. 2011
    ..This study investigated the effects of pioglitazone (PIO), ramipril (RAM), or their combination (PIRA) on low-grade inflammation in nondiabetic hypertensive patients with increased cardiovascular risk...
  37. ncbi Relaxin expression correlates significantly with serum changes in VEGF in response to antidiabetic treatment in male patients with type 2 diabetes mellitus
    Thomas Schondorf
    Institute of Clinical Research and Development, Mainz, Germany
    Clin Lab 53:193-8. 2007
    ..In women, other pathways may superimpose this effect. In conclusion, our study supports the hypothesis of different regulating pathways and effects of relaxin in men and women also in patients with type 2 diabetes...
  38. ncbi Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Parcusstr 8 D 55116 Mainz, Germany
    Expert Rev Cardiovasc Ther 4:445-59. 2006
    ..These results underline the value of pioglitazone for managing the increased cardiovascular risk of patients with a metabolic syndrome or Type 2 diabetes mellitus...
  39. ncbi Association of high-sensitive C-reactive protein with advanced stage beta-cell dysfunction and insulin resistance in patients with type 2 diabetes mellitus
    Andreas Pfutzner
    Institute for Clinical Research and Development, IKFE GmbH, Parcusstrasse 8, 55116 Mainz, Germany
    Clin Chem Lab Med 44:556-60. 2006
    ..Type 2 diabetes mellitus is associated with increased cardiovascular risk. One laboratory marker for cardiovascular risk assessment is high-sensitivity C-reactive protein (hsCRP)...
  40. ncbi Fasting intact proinsulin is a highly specific predictor of insulin resistance in type 2 diabetes
    Andreas Pfutzner
    Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Care 27:682-7. 2004
    ..This investigation explored the predictive value of intact proinsulin as an insulin resistance marker...
  41. ncbi Competact, a fixed combination of pioglitazone and metformin, improves metabolic markers in type 2 diabetes patients with insufficient glycemic control by metformin alone--results from a post-marketing surveillance trial under daily routine conditions
    Thomas Schondorf
    Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 11:379-83. 2009
    ....
  42. ncbi The switch from sulfonylurea to preprandial short- acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus
    Andreas Pfutzner
    IKFE, Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 8:375-84. 2006
    ..Supplementary insulin therapy provides assistance to meal-time insulin secretion in patients with type 2 diabetes and may have protective effects on beta-cell function...
  43. ncbi Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality
    Andreas Pfutzner
    Institut für Klinische Forschung und Entwicklung IKFE, Institute for Clinical Research and Development, Parcusstr 8, D 55116 Mainz, Germany
    Expert Opin Pharmacother 7:463-76. 2006
    ..Because of its additional microvascular and macrovascular effects, pioglitazone is an attractive and effective treatment option for the management of Type 2 diabetes mellitus...
  44. ncbi Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    Vasc Health Risk Manag 3:211-20. 2007
    ..The purpose of this review is to evaluate the clinical data that have been published on this combination, appearing to represent a convenient way to obtain therapeutic targets in patients with type 2 diabetes mellitus...
  45. ncbi Evaluation of CGMS during rapid blood glucose changes in patients with type 1 diabetes
    Birgit Wilhelm
    Institute for Clinical Research and Development, Johannes Gutenberg University, Mainz, Germany
    Diabetes Technol Ther 8:146-55. 2006
    ..CONCLUSIONS: Continuous glucose measurements using CGMS provide reliable glucose measurements even in the case of dynamic blood glucose changes...
  46. ncbi High-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazone
    Andreas Pfutzner
    IKFE, Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 4:706-16. 2010
    ....
  47. ncbi Intact and total proinsulin: new aspects for diagnosis and treatment of type 2 diabetes mellitus and insulin resistance
    Andreas Pfutzner
    Institute for Clinical Research and Development, Mainz, Germany
    Clin Lab 50:567-73. 2004
    ..Both assays can thus be used to assess beta-cell function, to facilitate the selection of the most promising therapy, and may also serve to monitor treatment success in the further course of the disease...
  48. ncbi Pilot study for assessment of optimal frequency for changing catheters in insulin pump therapy-trouble starts on day 3
    Volkmar Schmid
    IKFE CRO, Mainz, Germany
    J Diabetes Sci Technol 4:976-82. 2010
    ....
  49. ncbi Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    Expert Opin Pharmacother 8:1985-98. 2007
    ..They underline the value of this drug when used alone or in combination with other antidiabetic drugs for a successful management of Type 2 diabetes mellitus...
  50. ncbi Elevated peripheral visfatin levels in narcoleptic patients
    Norbert Dahmen
    Department of Psychiatry, University of Mainz, Mainz, Germany
    PLoS ONE 3:e2980. 2008
    ..Visfatin is a recently described proinflammatory adipokine. It is identical to the immune modulating pre-B-cell colony enhancing factor (PBEF). Our study examines the hypothesis that visfatin levels are altered in narcoleptic patients...
  51. ncbi Elevated intact proinsulin levels are indicative of Beta-cell dysfunction, insulin resistance, and cardiovascular risk: impact of the antidiabetic agent pioglitazone
    Andreas Pfutzner
    IKFE, Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 5:784-93. 2011
    ....
  52. ncbi Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance
    Andreas Pfutzner
    Institute of Clinical Research and Development, IKFE GmbH, Mainz, Germany
    Clin Lab 49:571-6. 2003
    ..It may, however, be concluded from this study that at least in cross-sectional epidemiological investigations, fasting human resistin concentrations are not significantly correlating with any clinical measure for insulin resistance...
  53. ncbi Evaluation of a new fully automated one-step C-peptide chemiluminescence assay (LIAISON C-Peptid)
    Andreas Pfutzner
    Institute for Clinical Research and Development, Mainz, Germany
    Clin Lab 49:227-32. 2003
    ..In general, the new LIAISON chemiluminescence assay compared favorably with the RIA and comparative chemiluminescence test and offers an attractive alternative for C-peptide analysis...
  54. ncbi A biomarker concept for assessment of insulin resistance, beta-cell function and chronic systemic inflammation in type 2 diabetes mellitus
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    Clin Lab 54:485-90. 2008
    ....
  55. ncbi Increased prevalence of cardiovascular disease and risk biomarkers in patients with unknown type 2 diabetes visiting cardiology specialists: results from the DIASPORA study
    Thomas Schondorf
    Institute for Clinical Research and Development, Mainz, Germany
    Diab Vasc Dis Res 7:145-50. 2010
    ..Patients with diabetes mellitus and IGT have a high risk for cardiovascular events. It is tempting to speculate that these patients are often first seen by cardiologists...
  56. ncbi Impact of posture and fixation technique on impedance spectroscopy used for continuous and noninvasive glucose monitoring
    Andreas Pfutzner
    Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 6:435-41. 2004
    ..Well-educated patients might be the best candidates for first using the device for continuous glucose monitoring. They may especially benefit from the trend indication and the hypoglycemia/hyperglycemia threshold and alarm functions...
  57. ncbi Determination of nitrotyrosine concentrations in plasma samples of diabetes mellitus patients by four different immunoassays leads to contradictive results and disqualifies the majority of the tests
    Michael Safinowski
    Institute for Clinical Research and Development, Mainz, Germany
    Clin Chem Lab Med 47:483-8. 2009
    ..The peroxynitrite concentrations can be indirectly monitored by the detection of nitrotyrosine residues in proteins, reflecting the extent of damage caused by oxidative stress...
  58. ncbi Development of a high throughput single nucleotide polymorphism screening method for the cytochrome P450 1A2 polymorphisms CYP1A2*1C and CYP1A2*1F: are they useful as predictive markers in mental disorders?
    Marco Klemm
    PharmGenomics GmbH, Mainz, Germany
    Clin Lab 56:473-80. 2010
    ....
  59. ncbi Evaluation of SET--a new device for the measurement of pain perception in comparison to standard measures of diabetic neuropathy
    Mai Nguyen
    Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 6:601-6. 2004
    ..82; vibration = 0.61; temperature = 0.42; light touch = 0.11). CONCLUSIONS: Measurement of pain perception threshold using the SET device is an easy and reliable method for identifying patients with impaired small nerve fiber function...
  60. ncbi Evaluation of dexterity in insulin-treated patients with type 1 and type 2 diabetes mellitus
    Julia Pfützner
    IKFE, Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 5:158-65. 2011
    ..Dexterity skills may play an important role in the performance efficacy of these procedures...
  61. ncbi Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism
    Andreas Pfutzner
    Institute for Clinical Research and Development, Parcusstr 8, D 55116 Mainz, Germany
    Expert Opin Drug Deliv 2:1097-106. 2005
    ..Provided a reliable long-term safety profile, TI may become a suitable alternative to subcutaneous injection for prandial insulin delivery. TI offers the possibility of new treatment regimens, especially in patients with Type 2 diabetes...
  62. ncbi Investigation of insulin resistance in narcoleptic patients: dependent or independent of body mass index?
    Alice Engel
    Department of Psychiatry, University of Mainz, Germany
    Neuropsychiatr Dis Treat 7:351-6. 2011
    ..Narcoleptic patients have been reported to suffer from an excess morbidity of Type 2 diabetes, even after correction for their often elevated body mass index...
  63. ncbi Laboratory evaluation of a new lateral-flow-based point-of-care rapid test for assessment of chronic systemic inflammation
    Renate Siebenhaar
    IKFE Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 4:717-22. 2010
    ..It may therefore be suitable for a fast and convenient screening, which, after laboratory test confirmation, may help to identify patients with elevated risk of macrovascular disease...
  64. ncbi Downregulation of the proinflammatory state of circulating mononuclear cells by short-term treatment with pioglitazone in patients with type 2 diabetes mellitus and coronary artery disease
    Andreas Pfutzner
    IKFE Institute for Clinical Research and Development, Research Laboratory, 55116 Mainz, Germany
    PPAR Res 2011:647017. 2011
    ....
  65. ncbi Analysis of the environmental impact of insulin infusion sets based on loss of resources with waste
    Andreas Pfutzner
    IKFE, Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 5:843-7. 2011
    ..The loss or resources with regular CSII is considerably lower than the loss or resources induced by patch pumps...
  66. ncbi Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus
    Andreas Pfutzner
    Institute for Clinical Research and Development, Mainz, Germany
    Diabetes Technol Ther 6:405-12. 2004
    ..Assessment of beta-cell function by determination of intact proinsulin may facilitate the selection of the most promising therapy and may also serve to monitor treatment success in the further course of the disease...
  67. ncbi Assessment of the mixing efficiency of neutral protamine Hagedorn cartridges
    Pia Kaiser
    IKFE, Institute for Clinical Research and Development, Mainz, Germany
    J Diabetes Sci Technol 4:652-7. 2010
    ..All other cartridges with fewer bullets were shown to deliver potentially harmful doses if used for treatment when the mixing procedure was less frequent than demanded in the instructions for use...
  68. ncbi Peripheral leptin levels in narcoleptic patients
    Norbert Dahmen
    Department of Psychiatry, University of Mainz, Mainz, Germany
    Diabetes Technol Ther 9:348-53. 2007
    ..Two studies have reported decreased leptin levels, whereas a larger, recent study failed to detect differences between patients and controls...
  69. ncbi IRIS II study: intact proinsulin is confirmed as a highly specific indicator for insulin resistance in a large cross-sectional study design
    Andreas Pfutzner
    University of Applied Sciences, Rheinbach, Germany
    Diabetes Technol Ther 7:478-86. 2005
    ..The cross-sectional IRIS-II study tried to assess the prevalence of insulin resistance and macrovascular disease in orally treated patients with Type 2 diabetes...
  70. ncbi High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus
    Andreas Pfutzner
    University of Applied Sciences, Rheinbach, Germany
    Diabetes Technol Ther 8:28-36. 2006
    ..Positive results in these trials will further strengthen the value and acceptance of hsCRP, which is recommended as a predictive laboratory marker for cardiovascular disease risk also in patients with diabetes mellitus...
  71. ncbi Cross-sectional investigation on the accuracy of alternate site glucose testing using the Soft-Sense glucose meter
    Andreas Pfutzner
    Institut für klinische Forschung und Entwicklung, Mainze
    Swiss Med Wkly 132:351-7. 2002
    ....
  72. ncbi Clinical and laboratory evaluation of specific chemiluminescence assays for intact and total proinsulin
    Andreas Pfutzner
    IKFE, Institute of Clinical Research and Development, Mainz, Germany
    Clin Chem Lab Med 41:1234-8. 2003
    ..Both CLIAs could be performed much faster (4 hours) than the RIA method (75 hours/ 4 days). In conclusion, the CLIA methods show improved qualitative outcomes, higher specificity and several technical advantages over the RIA method...
  73. ncbi Investigation on the accuracy of the blood glucose monitoring device Prestige IQ
    M Larbig
    Institut für Klinische Forschung und Entwicklung IKFE GmbH, Mainz, Germany
    Diabetes Nutr Metab 16:257-61. 2003
    ..In conclusion, Prestige IQ showed excellent performance with clinically acceptable accuracy and reliability as compared to both the laboratory reference and the four commercially available self-monitoring blood glucose systems...
  74. ncbi Stimulation of endothelial nitric oxide synthase by proinsulin C-peptide
    Thomas Wallerath
    Department of Pharmacology, Johannes Gutenberg University, Mainz, Germany
    Nitric Oxide 9:95-102. 2003
    ..We suggest that this effect may contribute to the increase in skin and muscle blood flow previously demonstrated in human in vivo...
  75. ncbi Effect of C-peptide on glucose metabolism in patients with type 1 diabetes
    Thomas Forst
    Diabetes Care 25:1096-7. 2002
  76. ncbi Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study
    Markolf Hanefeld
    GWT, Center for Clinical Studies, Dresden, Germany
    J Am Coll Cardiol 49:290-7. 2007
    ....
  77. ncbi Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy
    Christof Kazda
    Lilly Deutschland GmbH, Bad Homburg, Germany
    J Diabetes Complications 20:145-52. 2006
    ..To compare the effects of prandial insulin therapy focusing on postprandial glucose control vs. basal insulin therapy focusing on fasting glucose control in patients with type 2 diabetes...
  78. ncbi Development and validation of a new measure to evaluate psychological resistance to insulin treatment
    Frank Petrak
    Department for Psychosomatic Medicine and Psychotherapy, LWL Clinic Dortmund Ruhr University of Bochum, Dortmund, Germany
    Diabetes Care 30:2199-204. 2007
    ..To develop a psychometric questionnaire to measure psychological barriers to insulin treatment in patients with type 2 diabetes...
  79. ncbi The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions
    Efstrathios Karagiannis
    Takeda Pharma, Aachen, Germany
    Diabetes Technol Ther 10:206-12. 2008
    ..This observational trial was performed to evaluate the effects of pioglitazone on hsCRP values in a large population under daily life conditions...
  80. ncbi C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients
    Thomas Hach
    Department of Internal Medicine, University of Mainz, 55101 Mainz, Germany thomas
    Exp Diabetes Res 2008:730594. 2008
    ..This study aimed to investigate the influence of C-peptide and fragments thereof on erythrocyte deformability and to elucidate the relevant signal transduction pathway...
  81. ncbi Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana
    Susanne Röwer
    Institute of Tropical Medicine, Charite University Medicine Berlin, Berlin, Germany
    Trop Med Int Health 10:1271-3. 2005
    ..We did not detect CYP2C8*3 and CYP2C8*4, but CYP2C8*2 showed an allele frequency of 0.1675. AQ metabolism in patients with CYP2C8*2 may be impaired, and with an increase of AQ based treatment the risk of severe adverse events may mount...
  82. ncbi New tricks by an old dog
    Thomas Forst
    Exp Diabetes Res 2008:384219. 2008